Xilio Therapeutics, INC Form 4 insider transactions

Gilead Sciences, Inc., a 10% owner and director of Xilio Therapeutics, Inc., has acquired over 13 million units of prefunded and multi-series warrants, signaling a substantial investment in the biotechnology firm.

Rene Russo, CEO of Xilio Therapeutics, acquired 190,000 stock options on April 15, 2025, according to a recent SEC Form 4 filing.

Christopher James Frankenfield, CFO of Xilio Therapeutics, was granted stock options to purchase 75,000 shares of common stock.

Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, reports the vesting of restricted stock units and grant of stock options.

Christopher Frankenfield, CFO of Xilio Therapeutics, reports the vesting of restricted stock units, a sale of shares to cover tax obligations, and the grant of stock options.

Kevin M. Brennan, SVP, Finance and Accounting at Xilio Therapeutics, Inc., reports the vesting of restricted stock units, subsequent sale of shares to cover tax obligations, and grant of new stock options.

Rene Russo, CEO of Xilio Therapeutics, reports the vesting of restricted stock units and the grant of stock options.

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its beneficial ownership through the acquisition of common stock and prefunded warrants.

Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, acquired 26,000 stock options on October 1, 2024, exercisable at $0.75 per share.

Christopher James Frankenfield, Chief Operating Officer of Xilio Therapeutics, Inc., was granted 52,000 stock options on August 3, 2024.

Director Yuan Xu of Xilio Therapeutics acquired 25,000 stock options at an exercise price of $1.02 on June 14, 2024, according to a recent SEC filing.

Director Sara Bonstein of Xilio Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.02 on June 14, 2024.

Robert W. Ross, a director of Xilio Therapeutics, acquired stock options for 25,000 shares at an exercise price of $1.02 on June 14, 2024, according to a Form 4 filing.

Christina Rossi, a director of Xilio Therapeutics, reported the grant of a stock option for 25,000 shares on June 14, 2024.

Paul J. Clancy, a director of Xilio Therapeutics, reported the acquisition of a stock option for 25,000 shares on June 14, 2024.

Daniel J. Curran, a director of Xilio Therapeutics, acquired 25,000 stock options on June 14, 2024, according to a Form 4 filing with the SEC.

James Samuel Shannon, a director of Xilio Therapeutics, acquired 50,000 stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Aoife Brennan, a director of Xilio Therapeutics, acquired stock options for 50,000 shares of common stock on June 13, 2024.

Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, acquired stock options for 59,333 shares of common stock on May 1, 2024.

Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, was granted stock options for 20,000 shares on May 1, 2024.

Christopher James Frankenfield, Chief Operating Officer of Xilio Therapeutics, Inc., was granted stock options for 208,000 shares on May 1, 2024.

Rene Russo, CEO of Xilio Therapeutics, was granted stock options to purchase 474,000 shares of common stock on May 1, 2024.

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its beneficial ownership through the acquisition of common stock and prefunded warrants.